Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.
复制标题
DOI：
10.1371/journal.pone.0052261
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Felip E
中科院分区：
文献类型：
--
作者：
Martinez P;Hernández-Losa J;Montero MÁ;Cedrés S;Castellví J;Martinez-Marti A;Tallada N;Murtra-Garrell N;Navarro-Mendivill A;Rodriguez-Freixinos V;Canela M;Ramon y Cajal S;Felip E
间变性淋巴瘤激酶（ALK）阳性代表了非小细胞肺癌（NSCLC）亚组中的新分子靶点。我们探索荧光原位杂交（FISH）和免疫组化（IHC）作为ALK阳性患者的诊断方法，并描述其在NSCLC患者人群中的患病率和结局。选择既往在我们机构接受过表皮生长因子受体（EGFR）筛查的NSCLC患者。采用FISH技术鉴定ALK阳性患者，并探讨免疫组化（D5F3）检测ALK阳性的价值。确定了99名患者。中位年龄为61.5岁（范围35 - 83），均为白人，80%为腺癌，51%为男性，38%为当前吸烟者。7例（7.1%）患者经FISH检测为ALK阳性，13例（13.1%）患者为EGFR突变体，65例（65.6%）患者为ALK和EGFR阴性/野生型（WT）。ALK阳性和EGFR突变相互排斥。ALK阳性患者往往比EGFR突变或wt患者更年轻。ALK阳性患者主要为从不吸烟者（71.4%）和腺癌（71.4%）。ALK阳性和EGFR突变患者的结局优于阴性/WT患者。所有ALK FISH阴性肿瘤患者的ALK IHC均为阴性。在6例ALK FISH阳性且可用组织较多的患者中，5例ALK IHC阳性，1例阴性。ALK阳性患者占选定NSCLC人群的7.1%。ALK阳性患者具有不同的临床特征，并且结局优于EGFR WT和ALK阴性患者。IHC是检测ALK阳性NSCLC患者的一种有前途的方法。
Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and to describe its prevalence and outcomes in a population of NSCLC patients. NSCLC patients previously screened for Epidermal Growth Factor Receptor (EGFR) at our institution were selected. ALK positive patients were identified by FISH and the value of IHC (D5F3) was explored. ninety-nine patients were identified. Median age was 61.5 years (range 35–83), all were caucasians, eighty percent were adenocarcinomas, fifty-one percent were male and thirty-eight percent were current smokers. Seven (7.1%) patients were ALK positive by FISH, thirteen (13.1%) were EGFR mutant, and 65 (65.6%) were negative/Wild Type (WT) for both ALK and EGFR. ALK positivity and EGFR mutations were mutually exclusive. ALK positive patients tend to be younger than EGFR mutated or wt patients. ALK positive patients were predominantly never smokers (71.4%) and adenocarcinoma (71.4%). ALK positive and EGFR mutant patients have a better outcome than negative/WT. All patients with ALK FISH negative tumours were negative for ALK IHC. Out of 6 patients positive for ALK FISH with more tissue available, 5 were positive for ALK IHC and 1 negative. ALK positive patients represent 7.1% of a population of selected NSCLC. ALK positive patients have different clinical features and a better outcome than EGFR WT and ALK negative patients. IHC is a promising method for detecting ALK positive NSCLC patients.
登录
查看更多内容
影响因子：
6
作者：
Martelli, Maria Paola;Sozzi, Gabriella;Falini, Brunangelo
通讯作者：
Falini, Brunangelo
影响因子：
6.2
作者：
Lee, June Koo;Park, Heae Surng;Bang, Yung-Jue
通讯作者：
Bang, Yung-Jue
按地点划分的全球和区域癌症死亡率和发病率估计：II。 2000 年全球疾病负担的结果。
影响因子：
3.8
作者：
Shibuya, K;Mathers, CD;Boschi-Pinto, C;Lopez, AD;Murray, CJL
通讯作者：
Murray, CJL
DOI：
10.1158/1078-0432.ccr-10-0851
发表时间：
2010-11-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Camidge DR;Kono SA;Flacco A;Tan AC;Doebele RC;Zhou Q;Crino L;Franklin WA;Varella-Garcia M
通讯作者：
Varella-Garcia M
影响因子：
158.5
作者：
Rosell, Rafael;Moran, Teresa;Taron, Miquel
通讯作者：
Taron, Miquel